Johnson & Johnson (JNJ) Other Non-Current Assets (2009 - 2026)

Johnson & Johnson's (JNJ) quarterly Other Non-Current Assets came in at $14.1 billion in Q1 2026, up 22.29% year-on-year from $11.5 billion in Q1 2025, and down 1.83% quarter-over-quarter from $14.4 billion in Q4 2025.

Johnson & Johnson (JNJ) Other Non-Current Assets (2009 - 2026) Analysis & Trends

Johnson & Johnson has disclosed Other Non-Current Assets across 18 years of filings, most recently posting $14.1 billion for Q1 2026.

  • Other Non-Current Assets for Q1 2026 came in at $14.1 billion, up 22.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.1 billion (up 22.29% YoY), and the FY2025 annual result was $14.4 billion, up 25.88% from the prior year.
  • Other Non-Current Assets came in at $14.1 billion for Q1 2026 at Johnson & Johnson, down from $14.4 billion in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $27.2 billion in Q1 2023 to a low of $7.7 billion in Q2 2023.
  • The 5-year median for Other Non-Current Assets is $11.4 billion (2024), against an average of $12.3 billion.
  • Peak annual rise in Other Non-Current Assets reached 166.61% in 2023, while the deepest fall reached 48.04% in 2023.
  • Johnson & Johnson's Other Non-Current Assets stood at $8.6 billion in 2022, then surged by 64.09% to $14.2 billion in 2023, then fell by 19.35% to $11.4 billion in 2024, then grew by 25.88% to $14.4 billion in 2025, then fell by 1.83% to $14.1 billion in 2026.
  • The last three Other Non-Current Assets figures came in at $14.1 billion (Q1 2026), $14.4 billion (Q4 2025), and $12.4 billion (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Other Non-Current Assets (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn 3.18 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn 7.23 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn 14.11 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn 10.54 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn 19.81 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn 12.76 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn 4.55 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn 9.83 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn 6.08 Bn
10 Novartis Ag 109.78 Bn 109.09 Bn - 200.00 Mn

Historic Data

Download Data
DateValue
Mar 29, 2026 14.11 Bn
Dec 28, 2025 14.37 Bn
Sep 28, 2025 12.42 Bn
Jun 29, 2025 12.19 Bn
Mar 30, 2025 11.53 Bn
Dec 29, 2024 11.41 Bn
Sep 29, 2024 10.92 Bn
Jun 30, 2024 10.54 Bn
Mar 31, 2024 14.13 Bn
Dec 31, 2023 14.15 Bn
Jul 2, 2023 10.08 Bn
Apr 2, 2023 7.70 Bn
Jan 1, 2023 27.24 Bn
Oct 2, 2022 8.63 Bn
Jul 3, 2022 9.44 Bn
Apr 3, 2022 9.94 Bn
Jan 2, 2022 10.22 Bn
Oct 3, 2021 6.87 Bn
Jul 4, 2021 7.17 Bn
Apr 4, 2021 6.54 Bn